m2 10b4 crl 1972 cells (ATCC)
Structured Review
M2 10b4 Crl 1972 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 401 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/m2-10b4/M2-10B4/pm42020400-464-8-14
Average 95 stars, based on 401 article reviews
Images
Related Articles
Incubation:Article Title: A cytomegalovirus inflammasome inhibitor reduces proinflammatory cytokine release and pyroptosis Article Snippet: rp-ab99702.html Anti-Rat HRP (112-035-062), https://www.jacksonimmuno.com/catalog/products/112-035-062 M2-10B4 Flow Cytometry:Article Title: A cytomegalovirus inflammasome inhibitor reduces proinflammatory cytokine release and pyroptosis Article Snippet: rp-ab99702.html Anti-Rat HRP (112-035-062), https://www.jacksonimmuno.com/catalog/products/112-035-062 M2-10B4 Cytometry:Article Title: A cytomegalovirus inflammasome inhibitor reduces proinflammatory cytokine release and pyroptosis Article Snippet: rp-ab99702.html Anti-Rat HRP (112-035-062), https://www.jacksonimmuno.com/catalog/products/112-035-062 M2-10B4 Staining:Article Title: A cytomegalovirus inflammasome inhibitor reduces proinflammatory cytokine release and pyroptosis Article Snippet: rp-ab99702.html Anti-Rat HRP (112-035-062), https://www.jacksonimmuno.com/catalog/products/112-035-062 M2-10B4 Virus:Article Title: A cytomegalovirus inflammasome inhibitor reduces proinflammatory cytokine release and pyroptosis Article Snippet: rp-ab99702.html Anti-Rat HRP (112-035-062), https://www.jacksonimmuno.com/catalog/products/112-035-062 M2-10B4 Mouse Assay:Article Title: A cytomegalovirus inflammasome inhibitor reduces proinflammatory cytokine release and pyroptosis Article Snippet: rp-ab99702.html Anti-Rat HRP (112-035-062), https://www.jacksonimmuno.com/catalog/products/112-035-062 M2-10B4 Plaque Assay:Article Title: A cytomegalovirus inflammasome inhibitor reduces proinflammatory cytokine release and pyroptosis Article Snippet: rp-ab99702.html Anti-Rat HRP (112-035-062), https://www.jacksonimmuno.com/catalog/products/112-035-062 M2-10B4 Passaging:Article Title: A cytomegalovirus inflammasome inhibitor reduces proinflammatory cytokine release and pyroptosis Article Snippet: rp-ab99702.html Anti-Rat HRP (112-035-062), https://www.jacksonimmuno.com/catalog/products/112-035-062 M2-10B4 Recombinant:Article Title: A cytomegalovirus inflammasome inhibitor reduces proinflammatory cytokine release and pyroptosis Article Snippet: rp-ab99702.html Anti-Rat HRP (112-035-062), https://www.jacksonimmuno.com/catalog/products/112-035-062 M2-10B4 In Vivo:Article Title: A cytomegalovirus inflammasome inhibitor reduces proinflammatory cytokine release and pyroptosis Article Snippet: rp-ab99702.html Anti-Rat HRP (112-035-062), https://www.jacksonimmuno.com/catalog/products/112-035-062 M2-10B4 Control:Article Title: A cytomegalovirus inflammasome inhibitor reduces proinflammatory cytokine release and pyroptosis Article Snippet: rp-ab99702.html Anti-Rat HRP (112-035-062), https://www.jacksonimmuno.com/catalog/products/112-035-062 M2-10B4 Infection:Article Title: A cytomegalovirus inflammasome inhibitor reduces proinflammatory cytokine release and pyroptosis Article Snippet: rp-ab99702.html Anti-Rat HRP (112-035-062), https://www.jacksonimmuno.com/catalog/products/112-035-062 M2-10B4 |
46 ( N BM = 20, N LN = 14, and N PB = 26) and tested on RNAseq data of primary CLL cells cultured with and without M2‐10B4 cells. (D) Oncology‐related pathways (PROGENy) scored according to differential expression (DE) analysis of CLL cells cultured with and without M2‐10B4 cells. (E) NFKBIA expression in CLL cells cultured with and without M2‐10B4 cells according to RNAseq, tested by the limma voom algorithm with Benjamini–Hochberg correction. (F, G) Percentage of live (F) and IκBα + CLL (G) cells cultured with and without M2‐10B4 cells according to flow cytometry (FCM), tested by Friedman's test coupled with Dunn's post hoc test. (H) Volcano plot of gene expression detected in CLL cells co‐cultured with M2‐10B4 cells with and without PF‐670462 treatment. Blue dots—downregulated genes (adj. P‐value < 0.05, log 2 FC < −1) and red dots—upregulated genes (adj. P‐value < 0.05, log 2 FC > −1), with 10 most upregulated and 10 most downregulated genes labeled, tested by the limma voom algorithm with Benjamini–Hochberg correction. (I) Oncology‐related pathways (PROGENy) scored according to DE analysis of CLL cells co‐cultured with M2‐10B4 cells with and without PF‐670462 treatment. (J) NFKBIA expression in CLL cells co‐cultured with M2‐10B4 cells with and without PF‐670462 (PF‐67) treatment according to bulk RNAseq, tested by the limma voom algorithm with Benjamini–Hochberg correction. (K) Percentage of IκBα + CLL cells co‐cultured with M2‐10B4 cells with and without PF‐670462 treatment according to flow cytometry, tested by Friedman's test coupled with Dunn's post hoc test. (L–N) Heatmaps of expression changes in genes associated with nuclear factor κ B (NFκB) (L) , tumor necrosis factor α (TNFα) (M) , and phosphoinositide 3‐kinase (PI3K) (N) by the PROGENy model. CLL cells cultured with vs. without M2‐10B4 and CLL cells co‐cultured with M2‐10B4 treated with vs. without PF‐670462 were compared. (O) Seurat cell cycle scoring output shown for the G2/M phase, tested by Friedman's test coupled with Dunn's post hoc test (5 M cells were analyzed per sample). " width="250" height="auto" />